Disclaimer

This presentation has been prepared by IBA Health Group Limited and its subsidiaries ("IBA Group") in connection with a presentation to the ASX Small to Mid Caps London Thursday March 19.

The contents of this presentation are based on information publicly available as at the date of this presentation. This presentation should not be taken as an indication of the state of affairs of the IBA Group or its subsidiaries nor is it an indication that there will be or has been no change in the state of the affairs of the IBA Group or since the date of this presentation or since any other date at which any information contained in this presentation is expressed to be stated.

IBA Group is not under any obligation to correct, update or revise this presentation, or to provide recipients with access to any additional information. IBA Group does not make any warranty or representation regarding the accuracy, currency, completeness or fairness of the information contained in this presentation and so far as permitted by law no responsibility nor liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements negligent or otherwise relating thereto.

All estimates, prospects, returns and forward-looking statements represent the subjective views of management of the IBA Group and management's current estimates of future performance based on various assumptions which management believe are reasonable, but which may or may not prove to be correct. These assumptions are and will be subject to significant uncertainties and contingencies which are outside the control of the IBA Group. Recipients should make their own investigations and inquiries regarding assumptions, uncertainties and contingencies which may affect any of the securities, businesses or assets of the IBA Group. There can be no assurance that any estimates, prospects, returns and forward looking statements are attainable or will be realised. None of the IBA Group or any of their directors, employees or advisers nor any other person, shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on any statement in or omission from this document and any such liability is expressly disclaimed.

Nothing in the presentation should be construed as either an offer to sell or a solicitation of an offer to but or sell in any jurisdiction.
IBA Health Group Today

- Founded 1982
- Listed on ASX in 2000 (ASX: IBA)
- Included in S&P/ASX 200 Index
- 787 million shares on issue (46m convertibles)
- $124m 2 for 7 rights issues announced – 11 March
  - 150 million subscribed by institutions in rights issue
- Market value of GBP295 million (as at 16 March)
What Does IBA Health Do?

- Global leader in providing IT solutions to the healthcare industry
- Delivering solutions in **36 countries** across five continents
- 13,000+ installations
- 4,200 employees in 16 countries
- 31 strategic products, including **LORENZO** - the next generation health IT solution
A Stable and Resilient Core Business

- 90% of revenue is directly or indirectly government funded
- 94% of forecast FY09 revenue is recurring, contracted and expected
- A diverse global footprint (36 countries in five continents)
Streamlining our business

We have strategically realigned the business to focus on 3 market verticals, operating under the iSOFT brand.

- Positioned to deliver organic growth from our global footprint in existing and developing markets
- Growing the increasingly important emerging markets where healthcare in the community is a priority
Key Financials

NPAT

H1 08: -$1.1m
H1 09: $10.3m
H2 08 + H1 09: $26.1m

EBITDA

H1 08: $25.8m
H1 09: $67.5m
H2 08 + H1 09: $138.0m

Global Growth | Embracing the Global Opportunity
IBA Health’s stable and recurring revenues

Government policies and legislation are stimulating the global health IT industry. Up to 90% of our revenues are generated from government or government-supported contracts.

More than 60% of forecast FY09 revenues are recurring.

NPfIT (United Kingdom) - We are a key stakeholder in the world’s biggest public sector health IT project 13.4 billion pounds.
The Global Commitment to Health Spending

- Planned US$20 billion investment in US health IT infrastructure
  - US Government’s US$787 billion economic stimulus plan

- £13.4 billion NPfiT health IT spending program, servicing 60% of the UK National Health Service

- "Gulf region spends US$14 billion on healthcare projects".
  - Arabian Business.com, 19 January

- "China to spend US$124 billion on healthcare reform".
  - China Daily, 22 January

- Australian government’s A$218 million e-Health package

U. S.  |  UK  |  U. S.  |  Gulf Region |  China | Australia
A Resilient Global Health IT Industry

- Healthcare spending expected to outpace real GDP growth amid global recession
- Public sector health spending more resilient to global downturn than private sector
- Governments remain prompt and reliable payers

Public vs Private Sector Analysis

- **UK & Ireland**: 59% of Group Revenue
- **Asia, Middle East & Africa**: 12% of Group Revenue
- **Continental Europe**: 25% of Group Revenue
- **Australia & NZ**: 4% of Group Revenue

Public Sector vs Private Sector
Building on our Global Footprint

**SOUTHERN EUROPE & LATIN AMERICA**
- x-HIS product sold in Mexico and other Latin American countries.
- Exploring opportunities in Italy.

**iSOFT FINANCIAL**
- Financial product sold in Australia.
- Potential customers targeted in Australia, Asia, Middle East and Africa.

**CENTRAL EUROPE**
- Exploring opportunities for LabCentre in Australia and New Zealand, UK and Southeast Asia.

**UK & IRELAND**
- Exploring opportunities in Scandinavia and Commonwealth countries

**AUSTRALIA & SOUTHEAST ASIA**
- Primary care product bid in Asia, Middle East, Africa and the UK
- Exploring opportunities in Taiwan and Indonesia.
LORENZO – the next-generation transformational web-based IT solution.

• Brings healthcare into line with other industries.
• Removes barriers across the fragmented healthcare supply chain

Brings the right information, to the right provider, at the right time, to enhance patient’s experience through their healthcare journey.
LORENZO
LORENZO What makes it so good?

World’s only web-based healthcare IT product (Microsoft .NET)
Cost-effective:
• Scalable
• Modular
• Configurable
• Interoperable

A single product with a single source code with multiple solutions to meet any healthcare outcome across the entire supply chain.
LORENZO  What makes it so good?

• Designed to co-exist with existing systems and absorb them over time
• Enables systems to be upgraded and replaced incrementally
• Each subsequent release builds upon the previous
• Approach reduces the disruption to the organisation
• Reduces the risks associated with modernisation
• Provides lowest total cost of ownership
LORENZO Connecting the UK’s health industry

United Kingdom’s NPfIT

• World’s first procurement programme on behalf of an entire national health community.

• LORENZO will connect the patient records of 30 million people (60% of the British National Health Service).

• IBA Health will earn an estimated 315 million pounds from NPfIT over its lifetime (120 million pounds of this has already been earned).

• IBA’s development costs are underwritten by NPfIT.

• LORENZO live at two major early adopter sites.

• Increased rollout of LORENZO in 2H 2009.
Managing Our NPfIT Commitment

Renegotiated partnership agreement with CSC
- Approximately 80% of revenue comes from scheduled payments.
LORENZO – NPfIT (UK) Update

H1 Highlights:

✓ South Birmingham becomes first early adopter site to Go-Live with Release 1
✓ Morecambe Bay becomes second early adopter site to Go-Live with Release 1
✓ Release 2 delivered for testing to CSC on time

Milestones:

• Planned Go-Live at early adopter site at Bradford in Q1 09
• Planned Go-Lives for Release 2 at seven early adopter sites in Q3 09
H1 Highlights:

- Lorenzo Clinical v2.8 Go-Live in German and Dutch early adopter sites
- Lorenzo Clinical v3.0 delivered for Beta testing

Milestones:

- Lorenzo Clinical v3.0 planned Go-Live in Germany and Holland by Q4
- Lorenzo Clinical v3.0 introduction in Australia in FY 09
- Lorenzo Clinical v3.0 planned entry in additional countries in FY 09
LORENZO STUDIO The U.S. potential

- Highly privatised, fragmented U.S. healthcare providers.
  - software vendors
  - hospital groups
- LORENZO STUDIO is interoperable with existing health IT systems.
- Our presence at HIMSS 09 in Chicago in April.
Outlook & Guidance

FY09 guidance reaffirmed

- FY09 forecast revenue – in range of $540 – $560m\(^{(1)}\)
- FY09 forecast EBITDA – in range of $120 - $130m\(^{(1)}\)
- EBITDA margin of 23% – after FY09 expenditure for future growth
- On track to reinstate a dividend in FY 09
- Interest expense to reduce in H2

\(^{(1)}\)Assuming AUD / GBP 0.469; AUD / EURO 0.590; AUD / INR 39.000
Debt reduced by Capital Raising

<table>
<thead>
<tr>
<th>Currency</th>
<th>Dec '08 $m</th>
<th>Impact of institutional entitlement offer $m</th>
<th>Pro forma Dec '08 $m</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borrowings</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● Senior secured borrowings GBP</td>
<td>193.9</td>
<td>(7.7)</td>
<td>186.2</td>
<td>21-Aug-11</td>
</tr>
<tr>
<td>● Revolving bank facilities AUD</td>
<td>9.0</td>
<td>(9.0)</td>
<td>0.0</td>
<td>31-Jul-09</td>
</tr>
<tr>
<td>● Subordinated secured borrowings AUD</td>
<td>60.0</td>
<td>(60.0)</td>
<td>0.0</td>
<td>30-Jun-09</td>
</tr>
<tr>
<td>● Convertible notes payable AUD</td>
<td>31.7</td>
<td></td>
<td>31.7</td>
<td>31-Oct-12</td>
</tr>
<tr>
<td>● Contract funding GBP, EUR, AUD</td>
<td>68.5</td>
<td></td>
<td>68.5</td>
<td>2012</td>
</tr>
<tr>
<td>● Other Borrowings</td>
<td>1.5</td>
<td></td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>● Finance lease liability</td>
<td>1.4</td>
<td></td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td><strong>Total borrowings</strong></td>
<td><strong>366.0</strong></td>
<td><strong>(76.7)</strong></td>
<td><strong>289.3</strong></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>44.1</td>
<td>0.0</td>
<td>44.1</td>
<td></td>
</tr>
<tr>
<td>Total net debt</td>
<td>321.9</td>
<td><strong>(76.7)</strong></td>
<td>245.2</td>
<td></td>
</tr>
<tr>
<td>Total net debt (excluding subordinate &amp; convertible debt)</td>
<td>230.2</td>
<td><strong>(16.7)</strong></td>
<td>213.6</td>
<td></td>
</tr>
</tbody>
</table>

(1) Assuming AUD / GBP 0.469; AUD / EURO 0.590; AUD / INR 39.000
Gearing reduced by Capital Raising

<table>
<thead>
<tr>
<th></th>
<th>Pre Offer</th>
<th>Post Institutional Entitlement Offer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net debt to EBITDA</strong></td>
<td>2.3x</td>
<td>1.8x</td>
</tr>
<tr>
<td><strong>EBITDA to finance costs</strong></td>
<td>3.0x</td>
<td>4.0 x</td>
</tr>
<tr>
<td><strong>Gearing ratio (net debt/equity)</strong></td>
<td>45%</td>
<td>30%</td>
</tr>
</tbody>
</table>

(1) Assuming AUD / GBP 0.469; AUD / EURO 0.590; AUD / INR 39.000
Proposed New Name

iSOFT GROUP LIMITED (ASX: ISF)

• Align the company’s name with our major brand
• Embrace a common identity among our shareholders, customers and employees
• Subject to shareholder approval
In summary: IBA Health’s core strengths

- An innovative leader in a resilient global industry
  - Government support for healthcare IT spending
  - High-quality earnings - recurring revenues in low-risk public sector
  - Long-term contracts across a diverse international client base
  - A stakeholder in the world’s biggest civilian IT projects
  - LORENZO – the world’s leading health IT innovation
Questions

IBA Health Group

Andrea Fiumicelli
Chief Operations Officer

andrea.fiumicelli@isoftplc.com
www.ibahealth.com